Research

Quorum Sensing (QS) Targeted Drug Development against Bacterial Infections

We in our lab, are into the QS mediated alternative therapeutic approach for Antimicrobial resistance. The QS targeted drug development will evolve around the search for quorum sensing inhibitors (QSIs) to mitigate the pathogenesis without killing the bacteria and also overcome the emergence of multi-drug resistant (MDR) bacterial strains.

Ongoing

Nano-titanium based dental implant functionalized with novel biofilm inhibitors.

Funding Agency: MHRD SPARC

Completed

• Synthesis and biological evaluation of a novel quorum quencher, 2[(methylamino)methyl Phenol] in down regulating Staphylococcus species adhesion in bioimplants (2015-2017)

Funding Agency: ICMR-Adhoc

• Bioprospecting Rare Marine Actinobacteria (RMA) for anti-infectives to combat Vibrio cholera pathogenesis by targeting NtrC- family response regulator (2016-2019)

Funding Agency: DST-SERB

• Mimic AIP II as a therapeutic tool against S.aureus Pathogenesis (2009-2011)

Funding Agency: DST-Fast track

• Quorum Sensing Inhibitor from Melia dubia: An interceptor for UTI during pregnancy (2010-2012)

Funding Agency: DST-SERB

Inter

Dr. T. Ramamurthy, National Chair, THSTI

Dr. Sabu Thomas, RGCB, Trivandrum

Dr. M. N. Sumana, JSS Medical College, Mysore

Dr. Ashima Bharadwaj, Indian Institute of Advanced Research, Gujarat

Dr. Rambabu Dandela, IICT, Bhubaneswar

Intra

Dr. V. Sridharan, School of Chemical and Biotechnology, SASTRA

Dr. P. Vairaprakash, School of Chemical and Biotechnology, SASTRA

Prof. John Bosco Balaguru R, School of Electrical and Electronics Engineering, SASTRA

Prof. M. Sridharan, School of Electrical and Electronics Engineering, SASTRA

Industry

M/s. Indus Biotech Pvt. Ltd., Pune

International Collaborations

Dr. Prasanna Neelakantan, Faculty of Dentistry, University of Hong Kong

Prof. J P Matinlinna, Faculty of Dentistry, University of Hong Kong